Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase inhibitors, su...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 March 2018
|
| In: |
Annals of hematology
Year: 2018, Volume: 97, Issue: 8, Pages: 1357-1367 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-018-3295-8 |
| Online Access: | Resolving-System, Volltext: https://doi.org/10.1007/s00277-018-3295-8 Verlag: https://link.springer.com/article/10.1007%2Fs00277-018-3295-8 
|
| Author Notes: | Dong-Wook Kim, Susanne Saussele, Loretta A. Williams, Hesham Mohamed, Yuanxin Rong, Teresa Zyczynski, Javier Pinilla-Ibarz, Elisabetta Abruzzese |
| Summary: | Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase inhibitors, such as dasatinib, are available with the potential to reduce adverse events, improve tolerability, and support long-term treatment goals. We present the final, primary analysis of DASPERSE/CA180-400 (NCT01660906), an open-label, multicenter, phase IV study designed to determine whether chronic, low-grade nonhematologic adverse events in imatinib-treated patients improve after switching to dasatinib, without affecting efficacy. |
|---|---|
| Item Description: | Gesehen am 18.10.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-018-3295-8 |